Merck & Co. (MRK) : D. Scott Neal scooped up 143 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 666 shares of Merck & Co. which is valued at $39,154.Merck & Co. makes up approximately 0.03% of D. Scott Neal’s portfolio.
Other Hedge Funds, Including , Stralem Co Inc reduced its stake in MRK by selling 40,000 shares or 8.39% in the most recent quarter. The Hedge Fund company now holds 436,747 shares of MRK which is valued at $25,676,356. Merck & Co. makes up approx 2.90% of Stralem Co Inc’s portfolio.Beech Hill Advisors reduced its stake in MRK by selling 720 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 100,929 shares of MRK which is valued at $5,933,616. Merck & Co. makes up approx 3.86% of Beech Hill Advisors’s portfolio.North American Management Corp reduced its stake in MRK by selling 5,147 shares or 3.45% in the most recent quarter. The Hedge Fund company now holds 144,108 shares of MRK which is valued at $8,472,109. Merck & Co. makes up approx 1.37% of North American Management Corp’s portfolio.Partnerre Asset Management Corp reduced its stake in MRK by selling 100 shares or 0.53% in the most recent quarter. The Hedge Fund company now holds 18,776 shares of MRK which is valued at $1,108,160. Merck & Co. makes up approx 0.56% of Partnerre Asset Management Corp’s portfolio. Indiana Trust Investment Management Co added MRK to its portfolio by purchasing 3,813 company shares during the most recent quarter which is valued at $221,154. Merck & Co. makes up approx 0.12% of Indiana Trust Investment Management Co’s portfolio.
Merck & Co. opened for trading at $59 and hit $59.119 on the upside on Wednesday, eventually ending the session at $58.79, with a gain of 0.22% or 0.13 points. The heightened volatility saw the trading volume jump to 64,76,048 shares. Company has a market cap of $162,732 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.